ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2519

What Do We Know About Malignancies in IgA Vasculitis?

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 2200

Whole Blood Transcriptome Profiling in Juvenile Systemic Sclerosis Patients Reveals Active Immune Upregulation and Enhanced Fibrotic Signature

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2262

Window of Opportunity in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2124

WITHDRAWN

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2227

Worrisome Mortality Trends over 20 Years Among Patients with Underlying Ischemic Heart Disease and Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1800

WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes

SLE – Etiology & Pathogenesis Poster

1:00PM-2:30PM: Abstract Number: 2556

A Multi-center Study of Associations Between Neighborhood-Level Child Opportunity, Initial Disease Severity and Acute Care Utilization Among Children with SLE

Abstracts: Healthcare Disparities in Rheumatology

1:00PM-2:30PM: Abstract Number: 2589

A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease

Abstracts: ARP Interprofessional I: Epidemiology & Methods

1:00PM-2:30PM: Abstract Number: 2569

A Novel Hyperferritinemia Screen to Aid Differentiation of Hyperinflammatory Disorders

Abstracts: Pediatric Rheumatology – Clinical I

1:00PM-2:30PM: Abstract Number: 2587

A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications

Abstracts: ARP Interprofessional I: Epidemiology & Methods

1:00PM-2:30PM: Abstract Number: 2565

A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab-1000 and Prolia in Postmenopausal Women with Osteoporosis

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

1:00PM-2:30PM: Abstract Number: 2555

Addressing Economic Insecurities Could Improve Patient-Reported Outcomes in Lupus

Abstracts: Healthcare Disparities in Rheumatology

1:00PM-2:30PM: Abstract Number: 2583

Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study

Abstracts: SpA Including PsA – Treatment II

1:00PM-2:30PM: Abstract Number: 2572

Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Clinical I

1:00PM-2:30PM: Abstract Number: 2575

Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].